Literature DB >> 23050815

The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.

Terry Treadwell1, Hynda K Kleinman, David Crockford, Mark A Hardy, Giorgio T Guarnera, Allan L Goldstein.   

Abstract

Chronic nonhealing cutaneous wounds are a worldwide problem with no agent able to promote healing. A naturally occurring, endogenous repair molecule, thymosin beta 4 (Tβ4), has many biological activities that promote dermal repair. It is released by platelets at the site of injury and initiates the repair cascade. Tβ4 accelerated dermal healing of full-thickness punch wounds in various animal models, including normal rats and mice, steroid-treated rats, diabetic mice, and aged mice. Furthermore, in two phase 2 clinical trials of stasis and pressure ulcers, it was found to accelerate healing by almost a month in those patients that did heal. Tβ4 likely acts to repair and regenerate wounds by promoting cell migration and stem cell mobilization and differentiation, and by inhibiting inflammation, apoptosis, and infection. We conclude that Tβ4 is a multifunctional regenerative peptide important in dermal repair.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23050815     DOI: 10.1111/j.1749-6632.2012.06717.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.

Authors:  Sokho Kim; Jungkee Kwon
Journal:  J Physiol       Date:  2015-02-27       Impact factor: 5.182

Review 2.  Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.

Authors:  Li-Jin Chew; Cynthia A DeBoy
Journal:  Neuropharmacology       Date:  2015-06-24       Impact factor: 5.250

3.  Thymosin β4 overexpression regulates neuron production and spatial distribution in the developing avian optic tectum.

Authors:  Mael Lever; Carsten Theiss; Gabriela Morosan-Puopolo; Beate Brand-Saberi
Journal:  Histochem Cell Biol       Date:  2016-12-10       Impact factor: 4.304

Review 4.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

5.  Effects of thymosin β4 on a rat model of severe acute pancreatitis.

Authors:  Xiaobo He; Jia Yu; Wenyi Guo; Teng Zuo; Qiao Shi; Kailiang Zhao; Weixing Wang
Journal:  Exp Ther Med       Date:  2015-10-14       Impact factor: 2.447

6.  Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling.

Authors:  Jieun Kim; Jeongeun Hyun; Sihyung Wang; Chanbin Lee; Jae-Wook Lee; Eun-Yi Moon; Heejae Cha; Anna Mae Diehl; Youngmi Jung
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

Review 7.  Progress on the Function and Application of Thymosin β4.

Authors:  Yuan Xing; Yumeng Ye; Hongyan Zuo; Yang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-21       Impact factor: 5.555

8.  A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing.

Authors:  Tian-Jiao Xu; Qi Wang; Xiao-Wen Ma; Zhen Zhang; Wei Zhang; Xiao-Chang Xue; Cun Zhang; Qiang Hao; Wei-Na Li; Ying-Qi Zhang; Meng Li
Journal:  Drug Des Devel Ther       Date:  2013-10-01       Impact factor: 4.162

9.  Effects of exogenous thymosin β4 on carbon tetrachloride-induced liver injury and fibrosis.

Authors:  Xiankui Li; Lei Wang; Cai Chen
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.